JP2012053071A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012053071A5 JP2012053071A5 JP2011271607A JP2011271607A JP2012053071A5 JP 2012053071 A5 JP2012053071 A5 JP 2012053071A5 JP 2011271607 A JP2011271607 A JP 2011271607A JP 2011271607 A JP2011271607 A JP 2011271607A JP 2012053071 A5 JP2012053071 A5 JP 2012053071A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- registered trademark
- gelsolin
- multiple sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004878 Gelsolin Human genes 0.000 claims description 17
- 108090001064 Gelsolin Proteins 0.000 claims description 17
- 201000006417 multiple sclerosis Diseases 0.000 claims 7
- 102400000739 Corticotropin Human genes 0.000 claims 6
- 101800000414 Corticotropin Proteins 0.000 claims 6
- 229960000258 corticotropin Drugs 0.000 claims 6
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 6
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 4
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 4
- 108010050904 Interferons Proteins 0.000 claims 4
- 102000014150 Interferons Human genes 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229940079322 interferon Drugs 0.000 claims 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 4
- -1 fragmin Proteins 0.000 claims 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims 2
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- 108010027740 BHT 3009 Proteins 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 2
- 229930010555 Inosine Natural products 0.000 claims 2
- 108010005716 Interferon beta-1a Proteins 0.000 claims 2
- 108010005714 Interferon beta-1b Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 238000009171 T-cell vaccination Methods 0.000 claims 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 229940003504 avonex Drugs 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- 244000052616 bacterial pathogen Species 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 229960002436 cladribine Drugs 0.000 claims 2
- 229940038717 copaxone Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 229960002806 daclizumab Drugs 0.000 claims 2
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims 2
- 229960004976 desogestrel Drugs 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960002568 ethinylestradiol Drugs 0.000 claims 2
- WUWFMJLSHFBJBN-IBGZPJMESA-N ethyl (2s)-2-[(2,6-difluorobenzoyl)amino]-3-[4-(1,3,4-trimethyl-2,6-dioxopyrimidin-5-yl)phenyl]propanoate Chemical compound C([C@@H](C(=O)OCC)NC(=O)C=1C(=CC=CC=1F)F)C(C=C1)=CC=C1C1=C(C)N(C)C(=O)N(C)C1=O WUWFMJLSHFBJBN-IBGZPJMESA-N 0.000 claims 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 2
- 235000008191 folinic acid Nutrition 0.000 claims 2
- 239000011672 folinic acid Substances 0.000 claims 2
- 229960003776 glatiramer acetate Drugs 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 229960003786 inosine Drugs 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 229960001691 leucovorin Drugs 0.000 claims 2
- 229960001810 meprednisone Drugs 0.000 claims 2
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 229960004023 minocycline Drugs 0.000 claims 2
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims 2
- 229960001156 mitoxantrone Drugs 0.000 claims 2
- 229960005027 natalizumab Drugs 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 229960000331 teriflunomide Drugs 0.000 claims 2
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 claims 2
- 229940079023 tysabri Drugs 0.000 claims 2
- 229960003824 ustekinumab Drugs 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- QQKKFVXSQXUHPI-NBVRZTHBSA-N Acidissiminol epoxide Chemical compound O1C(C)(C)C1CC(O)C(/C)=C/COC(C=C1)=CC=C1CCNC(=O)C1=CC=CC=C1 QQKKFVXSQXUHPI-NBVRZTHBSA-N 0.000 claims 1
- 102000008704 Adseverin Human genes 0.000 claims 1
- 101150107838 Capg gene Proteins 0.000 claims 1
- FCHAMFUEENBIDH-UHFFFAOYSA-N Severin Natural products CC1CCC2C(C)C3CCC4(O)C(CC5C4CC(O)C6CC(CCC56C)OC(=O)C)C3CN2C1 FCHAMFUEENBIDH-UHFFFAOYSA-N 0.000 claims 1
- 102000019215 Supervillin Human genes 0.000 claims 1
- 108050006606 Supervillin Proteins 0.000 claims 1
- 101100440252 Xenopus laevis ncapg gene Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 229940087051 fragmin Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108010073419 scinderin Proteins 0.000 claims 1
- 108090000195 villin Proteins 0.000 claims 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78250906P | 2006-03-15 | 2006-03-15 | |
| US60/782,509 | 2006-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500495A Division JP2009530613A (ja) | 2006-03-15 | 2007-03-14 | 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012053071A JP2012053071A (ja) | 2012-03-15 |
| JP2012053071A5 true JP2012053071A5 (enExample) | 2017-06-01 |
| JP6203995B2 JP6203995B2 (ja) | 2017-09-27 |
Family
ID=38510104
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500495A Pending JP2009530613A (ja) | 2006-03-15 | 2007-03-14 | 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用 |
| JP2011271607A Active JP6203995B2 (ja) | 2006-03-15 | 2011-12-12 | 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500495A Pending JP2009530613A (ja) | 2006-03-15 | 2007-03-14 | 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8440622B2 (enExample) |
| EP (1) | EP2002258B1 (enExample) |
| JP (2) | JP2009530613A (enExample) |
| CN (1) | CN101460843B (enExample) |
| CA (1) | CA2680333C (enExample) |
| DK (1) | DK2002258T3 (enExample) |
| ES (1) | ES2651619T3 (enExample) |
| HU (1) | HUE035980T2 (enExample) |
| PL (1) | PL2002258T3 (enExample) |
| PT (1) | PT2002258T (enExample) |
| WO (1) | WO2007106577A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070238655A1 (en) * | 2003-11-12 | 2007-10-11 | The Trustees Of The University Of Pennsylvania | Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis |
| US9408891B2 (en) | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
| CN1980694B (zh) * | 2004-05-12 | 2012-09-26 | 布赖汉姆妇女医院有限公司 | 凝溶胶蛋白治疗感染的用途 |
| JP4348631B2 (ja) * | 2005-03-29 | 2009-10-21 | セイコーエプソン株式会社 | 半導体素子の製造方法 |
| US8198094B2 (en) | 2006-03-15 | 2012-06-12 | The Brigham And Women's Hospital, Inc. | Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis |
| EP2708603B1 (en) | 2008-01-25 | 2017-04-19 | The General Hospital Corporation | Diagnostic and therapeutic uses of gelsolin in renal failure |
| WO2009124226A2 (en) * | 2008-04-03 | 2009-10-08 | The Trustees Of The University Of Pennsylvania | Gelsolin uses in neurological disorders |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| DE102010026500A1 (de) * | 2010-07-07 | 2012-01-12 | Arthrogen Gmbh | Verfahren zur Herstellung von autologen Proteinen |
| WO2012081701A1 (ja) * | 2010-12-16 | 2012-06-21 | 独立行政法人産業技術総合研究所 | 髄液型糖タンパク質の富化及び分離方法、並びにその方法を用いた中枢神経系疾患用マーカーの探索方法及び中枢神経系疾患用マーカー |
| KR101416954B1 (ko) * | 2012-09-12 | 2014-07-16 | 한양대학교 산학협력단 | 조혈세포 분화 유도 방법 |
| US10161006B2 (en) | 2014-03-11 | 2018-12-25 | Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) | Diagnosis of hematologic diseases |
| FR3036188B1 (fr) * | 2015-05-12 | 2019-06-07 | Biomerieux | Prediction du risque de developper, pour des patients admis en service de reanimation, une infection disseminee |
| JP6947449B2 (ja) * | 2016-06-29 | 2021-10-13 | 学校法人自治医科大学 | バイオマーカー、診断用組成物、及び診断用キット |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| TWI697499B (zh) * | 2018-03-05 | 2020-07-01 | 中央研究院 | 用以診斷周邊神經病變的方法及套組 |
| WO2020263484A1 (en) * | 2019-06-28 | 2020-12-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuromyelitis optica spectrum diseases |
| CN116615216A (zh) * | 2020-09-23 | 2023-08-18 | 生物保护医疗公司 | 用于鉴定和治疗微粒相关疾病和病症的组合物和方法 |
| CA3196026A1 (en) * | 2020-09-23 | 2022-03-31 | Bioaegis Therapeutics Inc. | Compositions and methods for identifying and treating microparticle-associated diseases and conditions |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US627353A (en) * | 1899-06-20 | Cis robinson | ||
| US5071773A (en) * | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| CA2016227A1 (en) * | 1989-05-18 | 1990-11-18 | Xandra O. Breakefield | Genetic diagnosis of torsion dystonia |
| ES2124702T3 (es) | 1990-04-11 | 1999-02-16 | Brigham & Womens Hospital | Usos terapeuticos de compuestos que se unen a actina. |
| US5464817A (en) | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
| CA2063593A1 (en) | 1990-05-04 | 1991-11-05 | Biogen, Inc. | Multimeric gelsolin fusion constructs |
| US5571511A (en) * | 1990-10-22 | 1996-11-05 | The U.S. Government | Broadly reactive opsonic antibodies that react with common staphylococcal antigens |
| JP3507486B2 (ja) | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5360350A (en) * | 1991-08-23 | 1994-11-01 | The Whitaker Corporation | Sealant compositions and sealed electrical connectors |
| US5691160A (en) | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
| US5593964A (en) | 1993-10-07 | 1997-01-14 | The George Washington University Medical Center | Method of treating septic shock by preventing actin polymerization |
| JP3914272B2 (ja) | 1993-12-28 | 2007-05-16 | 中外製薬株式会社 | アドゼベリンをコードする遺伝子 |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US5846743A (en) * | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
| US5804427A (en) * | 1995-05-19 | 1998-09-08 | University Of Massachusetts | Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases |
| US5925529A (en) * | 1995-06-07 | 1999-07-20 | The Regents Of The University Of California | Method for discovery of peptide agonists |
| US5569588A (en) * | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| US5750353A (en) * | 1995-12-11 | 1998-05-12 | New England Medical Center Hospitals, Inc. | Assay for non-peptide agonists to peptide hormone receptors |
| DK0941108T3 (da) * | 1996-12-04 | 2002-11-18 | Renovo Ltd | Sårheling og behandling af fibrose |
| WO1998043630A1 (en) * | 1997-04-02 | 1998-10-08 | Brigham And Women's Hospital, Inc. | Means of ascertaining an individual's risk profile for atherosclerotic disease |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| US6409599B1 (en) | 1999-07-19 | 2002-06-25 | Ham On Rye Technologies, Inc. | Interactive virtual reality performance theater entertainment system |
| WO2002059604A2 (en) | 2001-01-26 | 2002-08-01 | Oxford Glycosciences (Uk) Ltd | Diagnosis and treatment of multiple sclerosis |
| EP1249244A1 (en) * | 2001-04-13 | 2002-10-16 | Universiteit Gent | Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease |
| EP2266595A3 (en) | 2002-02-06 | 2011-07-06 | Regenerx Biopharmaceuticals, Inc. | Treatment of infections and other disorders |
| WO2003088811A2 (en) | 2002-04-16 | 2003-10-30 | The Brigham And Women's Hospital, Inc. | Gelsolin as a prognostic marker of artherosclerotic diseases |
| WO2004001421A2 (en) * | 2002-06-21 | 2003-12-31 | Innogenetics N.V. | Method for the diagnosis and differential diagnosis of neurological diseases |
| WO2004023973A2 (en) | 2002-09-12 | 2004-03-25 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| US20050048574A1 (en) | 2003-03-14 | 2005-03-03 | Kantor Aaron B. | Biomarkers for diagnosing rheumatoid arthritis |
| US20070238655A1 (en) * | 2003-11-12 | 2007-10-11 | The Trustees Of The University Of Pennsylvania | Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis |
| US9408891B2 (en) * | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
| CN1980694B (zh) * | 2004-05-12 | 2012-09-26 | 布赖汉姆妇女医院有限公司 | 凝溶胶蛋白治疗感染的用途 |
| SG183012A1 (en) * | 2004-06-04 | 2012-08-30 | Genentech Inc | Method for treating multiple sclerosis |
| DK1929297T3 (da) * | 2005-09-29 | 2013-03-04 | Caprion Proteomics Usa Llc | Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse heraf |
| US8198094B2 (en) * | 2006-03-15 | 2012-06-12 | The Brigham And Women's Hospital, Inc. | Methods of using gelsolin levels to characterize a subject's risk of developing rheumatoid arthritis |
| EP2708603B1 (en) * | 2008-01-25 | 2017-04-19 | The General Hospital Corporation | Diagnostic and therapeutic uses of gelsolin in renal failure |
-
2007
- 2007-03-14 JP JP2009500495A patent/JP2009530613A/ja active Pending
- 2007-03-14 PT PT77532265T patent/PT2002258T/pt unknown
- 2007-03-14 EP EP07753226.5A patent/EP2002258B1/en active Active
- 2007-03-14 US US12/225,132 patent/US8440622B2/en active Active
- 2007-03-14 PL PL07753226T patent/PL2002258T3/pl unknown
- 2007-03-14 WO PCT/US2007/006581 patent/WO2007106577A2/en not_active Ceased
- 2007-03-14 CA CA2680333A patent/CA2680333C/en active Active
- 2007-03-14 ES ES07753226.5T patent/ES2651619T3/es active Active
- 2007-03-14 HU HUE07753226A patent/HUE035980T2/hu unknown
- 2007-03-14 DK DK07753226.5T patent/DK2002258T3/en active
- 2007-03-14 CN CN200780017675.5A patent/CN101460843B/zh active Active
-
2011
- 2011-12-12 JP JP2011271607A patent/JP6203995B2/ja active Active
-
2013
- 2013-04-12 US US13/861,578 patent/US20130230455A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230149512A1 (en) | Low dose il-2 for treating autoimmune-related or inflammatory disorders | |
| Sands et al. | Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn’s disease: a phase 2a study | |
| US10765723B2 (en) | Use of low dose IL-2 for treating autoimmune—related or inflammatory disorders | |
| JP2016147856A5 (enExample) | ||
| JP2020128375A (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| Metzler et al. | Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study | |
| Sellam et al. | Refractory multicentric reticulohistiocytosis treated by infliximab: two cases | |
| Ormaechea et al. | Safety of systemic therapy for noninfectious uveitis | |
| Mazza et al. | Innovative uses of tumor necrosis factor α inhibitors | |
| Ursini et al. | Old but good: modified-release prednisone in rheumatoid arthritis | |
| US12037389B2 (en) | Compositions for interferon blockade and methods of using same | |
| Savvidaki et al. | Replacement of mycophenolate acid with everolimus in patients who became neutropenic after renal transplant | |
| Glaubitz et al. | Update on myositis therapy: from today’s standards to tomorrow’s possibilities | |
| Añaños-Urrea et al. | Interactions between multiple sclerosis and pregnancy. Current landscape of approved treatments | |
| Wüst et al. | Preventive treatment with methylprednisolone paradoxically exacerbates experimental autoimmune encephalomyelitis | |
| Uda et al. | Tocilizumab postpones the start of hemodialysis compared to conventional oral treatment in amyloid A amyloidosis patients with advanced renal insufficiency by suppressing serum SAA levels | |
| CN116685351A (zh) | Empacta的结果：一项用于评估托珠单抗在患有covid-19肺炎的住院患者中的功效和安全性的随机、双盲、安慰剂对照、多中心研究 | |
| MacLean et al. | Immunologic therapy for relapsing-remitting multiple sclerosis | |
| Marta et al. | Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report | |
| Rhyou et al. | A case of episodic angioedema with eosinophilia controlled by anti-IL5 receptor antibody treatment | |
| Sarhan | Let us know how access to this document benefits you. | |
| King | Clinical edge: Treatment of multiple sclerosis with lemtrada | |
| Rizvi | Multiple sclerosis: current and future treatment options | |
| Green et al. | Systemic Corticosteroids in Asthma | |
| CN114980901A (zh) | 使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法 |